Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 13th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 13th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

March 1st 2016

What We're Reading: New HCV Drug Fails to Generate Excitement

AJMC Staff

What we're reading, March 1, 2016: physicians greet Merck's new hepatitis C drug with caution; 20% of Puerto Ricans could be infected with the Zika virus in 2016; and nearly $3 billion wasted in cancer medicines.

February 29th 2016

Healthcare Challenges and Solutions Discussed at the PAN-AJMC Cost-Sharing Roundtable

Surabhi Dangi-Garimella, PhD

The event saw participation by patient advocacy groups, health economists, health policy researchers, and patient advocacy groups-the primary interest of the participants was to identify the healthcare-associated economic hardships faced by patients and their caregivers across therapeutic areas and discuss potential solutions that could help alleviate some of this burden.

February 29th 2016

Chemotherapy Alone Post Surgery Provides Better Value in Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

Research led by investigators at the Vanderbilt University Medical Center has concluded that adjuvant chemotherapy improved survival compared with patients who received adjuvant chemoradiation in pancreatic cancer.

February 27th 2016

This Week in Managed Care: February 27, 2016

February 26th 2016

Making Healthcare Affordable Again - the Promise of Consumer Health Loans

Surabhi Dangi-Garimella, PhD

A new proposal from researchers at MIT and Dana-Farber offers a remedy for patients to cover high healthcare costs: securitized consumer healthcare loans.

February 25th 2016

Survival of the Fittest: Oncology Could Gain From Chemotherapy's Selective Force

Surabhi Dangi-Garimella, PhD

A new study questions the maximum-tolerated-dose approach in cancer.

February 25th 2016

Daniel J. Klein Highlights Barriers to Accessing Innovative Oncology Care

There are multiple barriers to accessing innovative oncology care from the design of healthcare benefits to a patient’s position on the federal poverty level, explained Daniel J. Klein, president and CEO of the Patient Access Network (PAN) Foundation.

February 25th 2016

New Triage System Reduces ER Visits of Oncology Patients

Brenna Diaz

Emergency room overutilization is a significant issue in oncology care and may increase healthcare expenditures while lowering the quality of patient care.

February 24th 2016

Brain Tumors Most Common Cause of Cancer Deaths in AYAs

Surabhi Dangi-Garimella, PhD

A collaborative study conducted across cancer treatment centers in the United States has identified malignant brain tumors as the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39 years.

February 24th 2016

What We're Reading: Drug Makers File Incomplete Side Effects Reports

AJMC Staff

What we're reading: drug makers are not reporting complete information about side effects; Johnson & Johnson will pay $72 million to the family of a woman who blamed her ovarian cancer on talcum powder; and Maine and Utah make new attempts at expanding Medicaid.

February 24th 2016

Investment in the National Cancer Moonshot - Hit or Miss?

Priyam Vora

Experts and biological researchers aren’t completely convinced with the president's cancer moonshot initiative and the released budget.

February 24th 2016

Income Inequality Contributes to Pediatric ALL Relapse

Surabhi Dangi-Garimella, PhD

Survival in children with acute lymphoblastic leukemia could be significantly influenced by their family’s socioeconomic status, a new study published in Pediatric Blood and Cancer has found.

February 23rd 2016

COA's Ted Okon to Discuss Oncology Trends in AJMC's February Tweetchat

Ted Okon, MBA, of the Community Oncology Alliance, will participate in a tweetchat with The American Journal of Managed Care on February 29, 1-2 pm ET, to discuss the 340B program, payment reform, the Oncology Medical Home, and more.

February 23rd 2016

BMJ Finds No Link Between Incretins and Pancreatic Cancer, but Debate Likely to Continue

Mary Caffrey

BMJ's study found no link bewteen incretin-based drugs and pancreatic cancer but said because of the latency of the cancer, adverse effects would have to be watched.

February 23rd 2016

Cancer-Specific Racial Disparities Persist Despite Overall Progress

Surabhi Dangi-Garimella, PhD

A new report by the American Cancer Society points to disparities in cancer survival between whites and blacks for certain cancers, although the reasons for these differences remain unconfirmed.

February 22nd 2016

Clinician Support Tool for Discussions on Cancer Care Costs

Surabhi Dangi-Garimella, PhD

The online tool includes worksheets for the most commonly used cancer treatment protocols that care providers can directly access through the electronic health record.

February 22nd 2016

Expanded Label for Palbociclib in Relapsed, Advanced Breast Cancer

Surabhi Dangi-Garimella, PhD

The supplemental new drug application submitted by Pfizer, the drug's manufacturer, included phase 3 results from the PALOMA-3 trial.

February 22nd 2016

What We're Reading: Seeking a Moratorium on New Drug Ads

AJMC Staff

What we're reading, February 22, 2016: new legislation proposes placing a 3-year moratorium on advertising newly approved drugs; the prevalence and incidence of stroke among young adults has increased significantly; and more women with breast cancer are choosing outpatient mastectomies.

February 22nd 2016

Procedural Vote May Push Califf Through to Lead the FDA

Surabhi Dangi-Garimella, PhD

Support from at least 60 senators during today's procedural vote will ensure a final confirmation vote for Robert Califf, MD, likely Tuesday.

February 20th 2016

This Week in Managed Care: February 20, 2016

This week's top managed care stories included the release of 7 core sets of quality measures, more evidence that value-based insurance design works to lower costs, and the FDA assigns breakthrough designation to AstraZeneca's PD-L1 inhibitor.

February 19th 2016

Patients With Head and Neck Cancer Face Lifestyle Alterations and Poor Survival

Surabhi Dangi-Garimella, PhD

Two studies presented at the ongoing 2016 Multidisciplinary Head and Neck Cancer Symposium report on financial hurdles faced by patients diagnosed with head and neck cancer that result in lifestyle modifications, advanced disease, and worse outcomes.

February 18th 2016

Immuno-Oncology Agents Are Not Above Resistance, Study Shows

Surabhi Dangi-Garimella, PhD

A new study, published in Nature Communications, has delineated a mechanism that could help explain the resistance that is emerging with the new immuno-oncology agents such as PD-1 and PD-L1.

February 17th 2016

Task Force Recommends Post-Operative Colonoscopy Over Endoscopy for Improved Outcomes in CRC

Surabhi Dangi-Garimella, PhD

A Task Force composed of gastroenterology specialists, with a special interest in colorectal cancer, has released updated recommendations urging post-operative colonoscopy instead of endoscopy to improve survival.

February 17th 2016

Anti—PD-L1 Agent, Durvalumab, Gets Breakthrough for Bladder Cancer

AJMC Staff

Durvalumab is being developed for the treatment of PD-L1—positive patients with inoperable or metastatic urothelial bladder cancer

February 17th 2016

AJMC's Evidence-Based Oncology Takes a Fresh Look at Massive Impact of Immuno-Oncology

Evidence-Based Oncology, the multistakeholder publication of The American Journal of Managed Care devoted to cancer care, revisits the rapidly evolving field of immuno-oncology in its current issue. While one author calls the clinical impact of “tsunami proportions,” the healthcare system is grappling with how to pay for these therapies.

February 16th 2016

CMS' Core Oncology Measures - A Work in Progress

Surabhi Dangi-Garimella, PhD

CMS, in collaboration with a working group of national organizations, has developed a set of Medical Oncology Measures to improve quality of care and avoid redundancy for providers of care.

February 16th 2016

Humana Uncommitted on Cologuard Test, Faces Lawsuit

Surabhi Dangi-Garimella, PhD

A noninvasive colorectal cancer screening test manufactured by Exact Sciences, which received CMS coverage within months of its FDA approval, is not included under Humana’s coverage policy

February 15th 2016

Shortcomings of Written Informed Consent Forms

Jackie Syrop

Relatively simple improvements could increase patient satisfaction and potentially improve the important process of imparting patient information during enrollment of cancer patients into clinical trials.

February 15th 2016

Study Identifies Biomarkers and Potential Targets in Obesity-Associated Cancers

Surabhi Dangi-Garimella, PhD

Inhibiting the PIGF/VEGFR-1 signaling regressed tumor growth in obese, but not in lean mice, the author report.

February 12th 2016

Socioeconomic Status an Important Determinant of HPV Vaccination

Surabhi Dangi-Garimella, PhD

A study published in Cancer Epidemiology, Biomarkers & Prevention has identified geographic and ethnic factors as an important determinant of vaccinating against the human papillomavirus.

...

109 110 111 112 113 114 115 116 117

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions